Related Experiment Video
Updated: Mar 31, 2026

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Kinase Inhibitors that Increase the Sensitivity of Methicillin Resistant Staphylococcus aureus to β-Lactam
Jay Vornhagen1,2,3, Kellie Burnside4, Christopher Whidbey5,6,7
1Department of Pediatric Infectious Diseases, University of Washington School of Medicine, Seattle, WA 98195, USA. jay.vornhagen@seattlechildrens.org.
Abstract:
Staphylococcus aureus are Gram-positive bacteria that are the leading cause of recurrent infections in humans that include pneumonia, bacteremia, osteomyelitis, arthritis, endocarditis, and toxic shock syndrome. The emergence of methicillin resistant S. aureus strains (MRSA) has imposed a significant concern in sustained measures of treatment against these infections. Recently, MRSA strains deficient in expression of a serine/threonine kinase (Stk1 or PknB) were described to exhibit increased sensitivity to β-lactam antibiotics. In this study, we screened a library consisting of 280 drug-like, low-molecular-weight compounds with the ability to inhibit protein kinases for those that increased the sensitivity of wild-type MRSA to β-lactams and then evaluated their toxicity in mice. We report the identification of four kinase inhibitors, the sulfonamides ST085384, ST085404, ST085405, and ST085399 that increased sensitivity of WT MRSA to sub-lethal concentrations of β-lactams. Furthermore, these inhibitors lacked alerting structures commonly associated with toxic effects, and toxicity was not observed with ST085384 or ST085405 in vivo in a murine model. These results suggest that kinase inhibitors may be useful in therapeutic strategies against MRSA infections.
Insights
Four novel kinase inhibitors enhance susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) to beta-lactam antibiotics. These compounds show promise for new MRSA infection therapies with low toxicity in preliminary studies.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Staphylococcus aureus is a leading cause of recurrent human infections.
- Methicillin-resistant S. aureus (MRSA) poses a significant therapeutic challenge.
- MRSA strains lacking serine/threonine kinase (Stk1/PknB) show increased sensitivity to beta-lactam antibiotics.
Purpose of the Study:
- To identify kinase inhibitors that increase MRSA sensitivity to beta-lactam antibiotics.
- To evaluate the in vivo toxicity of identified kinase inhibitors.
Main Methods:
- Screening of 280 low-molecular-weight kinase inhibitors against wild-type MRSA.
- Testing inhibitor efficacy in combination with sub-lethal beta-lactam concentrations.
- Assessing compound toxicity in a murine model.
Main Results:
- Identified four sulfonamide kinase inhibitors (ST085384, ST085404, ST085405, ST085399) that enhance WT MRSA sensitivity to beta-lactams.
- Inhibitors lacked common toxic structural alerts.
- No in vivo toxicity observed for ST085384 and ST085405 in mice.
Conclusions:
- Kinase inhibitors can re-sensitize MRSA to beta-lactam antibiotics.
- Specific sulfonamide compounds demonstrate potential as adjuncts for MRSA treatment.
- Further investigation into these kinase inhibitors for MRSA therapeutic strategies is warranted.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis

